The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for many primary care providers. Between 2011 and 2023, obesity-specific prescriptions for GLP-1s increased by 700%. Since then, roughly 1 in 5 Americans have reportedly taken these drugs to lose weight…
Leave a Comment Leave a Comment
